Mathew Verghese, Frye Robert L, Lennon Ryan, Barsness Greg W, Holmes David R
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Am J Cardiol. 2004 Feb 15;93(4):399-403. doi: 10.1016/j.amjcard.2003.10.031.
The influence of diabetic treatment status on long-term outcome after percutaneous coronary intervention (PCI) is unclear. Previous reports have suggested that patients who receive insulin treatment have worse long-term outcome compared with patients who do not need insulin. To determine the influence of diabetes treatment status on outcome after PCI, patients with diabetes mellitus who underwent successful PCI from January 1, 1996, to June 30, 2001, were divided into 2 groups based on whether or not they required insulin; patients with shock or recent (< or =7 days) myocardial infarction were excluded. Cox proportional hazards models were utilized to estimate the association between diabetes treatment status and long-term survival. One thousand one hundred four eligible diabetic patients were identified and divided into those treated with insulin (418 patients; median follow-up 35.5 months) and those treated with either an oral agent or diet alone (686 patients; median follow-up 27.9 months). Insulin-treated patients were less likely to be men, and had more previous coronary revascularizations, prior myocardial infarctions, and congestive heart failure on presentation. Angiographic and procedural characteristics were comparable. Unadjusted survival curves were constructed, demonstrating that insulin treatment was associated with worse survival than noninsulin treatment (p = 0.001). After adjusting for differences in baseline characteristics, insulin treatment did not adversely effect survival (odds ratio 1.10, 95% confidence intervals 0.77 to 1.58). Thus, among diabetic patients who underwent successful PCI, patients treated with insulin had worse survival. After adjusting for differences in baseline characteristics, insulin treatment was not independently associated with worse survival.
糖尿病治疗状态对经皮冠状动脉介入治疗(PCI)后长期预后的影响尚不清楚。既往报告提示,接受胰岛素治疗的患者与无需胰岛素治疗的患者相比,长期预后更差。为确定糖尿病治疗状态对PCI后预后的影响,将1996年1月1日至2001年6月30日期间成功接受PCI的糖尿病患者,根据是否需要胰岛素分为两组;排除休克或近期(≤7天)心肌梗死患者。采用Cox比例风险模型评估糖尿病治疗状态与长期生存之间的关联。共确定1104例符合条件的糖尿病患者,分为接受胰岛素治疗组(418例患者;中位随访35.5个月)和接受口服药物或单纯饮食治疗组(686例患者;中位随访27.9个月)。接受胰岛素治疗的患者男性比例较低,既往冠状动脉血运重建、既往心肌梗死及就诊时充血性心力衰竭的发生率更高。血管造影和手术特征具有可比性。构建未调整的生存曲线,显示胰岛素治疗与非胰岛素治疗相比,生存情况更差(p = 0.001)。在对基线特征差异进行调整后,胰岛素治疗对生存无不利影响(比值比1.10,95%置信区间0.77至1.58)。因此,在成功接受PCI的糖尿病患者中,接受胰岛素治疗的患者生存情况更差。在对基线特征差异进行调整后,胰岛素治疗与较差的生存无独立关联。